Another humanized monoclonal antibody RG7356, ... - CLL Support

CLL Support

22,367 members38,474 posts

Another humanized monoclonal antibody RG7356, in development by Roche

AussieNeil profile image
AussieNeilAdministrator
0 Replies

Roche are developing RG7356, which targets CD44, a surface receptor that is over-expressed in ZAP-70 positive CLL patients as well as some solid tumours. If early phase clinical trials proceed and show promise, this could be good news for ZAP-70 positive patients, given the generally poorer prognosis associated with this marker.

The full paper is available from the on-line edition of the Proceedings of the National Academy of Sciences:

pnas.org/content/110/15/612...

Neil

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Monoclonal antibody infusion

testing positive on lateral flow tests at the moment but coping well. I have now also tested...

Access to Monoclonal Antibody Treatment in Mexico

healthy. No antibodies after first 2 Pfizers, positive for antibodies after third shot. Will be...

Clinical trial with monoclonal antibodies?

Monoclonal antibodies vs. Paxlovid

Calling UK CLLers - Is government about to abandon support for protective monoclonal antibodies?

immunocompromised people, including CLL patients, in the invidious position of needing to shield...